Recently, it was reported that some patients with leukemia were resistant to CD19 CAR T-cell therapy due to defects in death-receptor signaling (27) and we wondered if this might account for the resistance of G164 cells to the CAR T cells. The gene discussed is CD19; the disease is leukemia.